CHARACTERIZATION OF NOVEL CYP2A6 POLYMORPHIC ALLELES (CYP2A6*18 AND CYP2A6*19) THAT AFFECT ENZYMATIC ACTIVITY
Open Access
- 1 August 2005
- journal article
- clinical trial
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 33 (8) , 1202-1210
Abstract
Genetic polymorphisms of CYP2A6 gene are known as a causal factor of the interindividual differences in nicotine metabolism. We found three novel CYP2A6 alleles. The CYP2A6*18A allele has a single nucleotide polymorphism (SNP) of A5668T (A1175T, Y392F) in exon 8. The CYP2A6*18B allele has synonymous SNPs of G51A (G51A), T5684C (T1191C), and T5702C (T1209C) in addition to A5668T (A1175T, Y392F). The CYP2A6*19 allele has the SNPs of A5668T (A1175T, Y392F), T6354C (intron 8), and T6558C (T1412C, I471T) as well as the conversion with the CYP2A7 sequence in the 3′-untranslated region, in which the latter two changes correspond to CYP2A6*7. Ethnic differences in the frequencies of these alleles were observed between whites, African-Americans, Japanese, and Koreans. Wild or variant CYP2A6 (CYP2A6*18, CYP2A6*19, and CYP2A6*7) were expressed in Escherichia coli. For coumarin 7-hydroxylation and 5-fluorouracil formation from tegafur, the Km values were increased, and Vmax values were decreased in CYP2A6.18 compared with those in CYP2A6.1, resulting in decreased clearance to 50 and 35% of that of the wild type, respectively. The Km and Vmax values for nicotine C-oxidation were both increased, resulting in no change of clearance. In CYP2A6.19, the effects on the coumarin 7-hydroxylation and 5-fluorouracil formation (increased Km and decreased Vmax) were prominent, resulting in decreased clearance to 8% of those of the wild type. For nicotine C-oxidation, the Km and Vmax values were both decreased, resulting in decreased clearance to 30% of that of the wild type. The changes of the kinetics in CYP2A6.19 were similar to those in CYP2A6.7. In vivo nicotine metabolism was evaluated in whites (n = 56) and Koreans (n = 40). Although the CYP2A6*18 and CYP2A6*19 alleles were found only heterozygously, a subject with CYP2A6*7/CYP2A6*19 showed a lower cotinine/nicotine ratio of the plasma concentration compared with homozygotes of the CYP2A6*1A, supporting the in vitro results that the CYP2A6*19 allele leads to decreased enzymatic activity.Keywords
This publication has 38 references indexed in Scilit:
- Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokersCarcinogenesis, 2004
- Novel human CYP2A6 alleles confound gene deletion analysisFEBS Letters, 2004
- Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysemaThorax, 2003
- Characterization of a novelCYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activityHuman Mutation, 2002
- INTERINDIVIDUAL DIFFERENCES IN NICOTINE METABOLISM AND GENETIC POLYMORPHISMS OF HUMAN CYP2A6Drug Metabolism Reviews, 2002
- CYP2A6*6, a Novel Polymorphism in Cytochrome P450 2A6, Has a Single Amino Acid Substitution (R128Q) That Inactivates Enzymatic ActivityJournal of Biological Chemistry, 2001
- A Novel Single Nucleotide Polymorphism Altering Stability and Activity of CYP2A6Biochemical and Biophysical Research Communications, 2001
- Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolismFEBS Letters, 1999
- The CYP2 family: models, mutants and interactionsXenobiotica, 1998
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976